Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy.
Brkic S, Stivala S, Santopolo A, Szybinski J, Jungius S, Passweg JR, Tsakiris D, Dirnhofer S, Hutter G, Leonards K, Lischer HEL, Dettmer MS, Neel BG, Levine RL, Meyer SC. Brkic S, et al. Among authors: meyer sc. Leukemia. 2021 Oct;35(10):2875-2884. doi: 10.1038/s41375-021-01391-2. Epub 2021 Sep 3. Leukemia. 2021. PMID: 34480104 Free PMC article.
Severe cutaneous toxicity related to Eltrombopag.
Meyer SC, Rovó A, Tsakiris DA, Scherer K, Tichelli A, Holbro A. Meyer SC, et al. Br J Haematol. 2013 Feb;160(3):412-4. doi: 10.1111/bjh.12126. Epub 2012 Nov 15. Br J Haematol. 2013. PMID: 23151239 Free article. No abstract available.
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.
Waibel M, Solomon VS, Knight DA, Ralli RA, Kim SK, Banks KM, Vidacs E, Virely C, Sia KC, Bracken LS, Collins-Underwood R, Drenberg C, Ramsey LB, Meyer SC, Takiguchi M, Dickins RA, Levine R, Ghysdael J, Dawson MA, Lock RB, Mullighan CG, Johnstone RW. Waibel M, et al. Among authors: meyer sc. Cell Rep. 2013 Nov 27;5(4):1047-59. doi: 10.1016/j.celrep.2013.10.038. Epub 2013 Nov 21. Cell Rep. 2013. PMID: 24268771 Free PMC article.
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, Xu K, Manova K, Pankov D, O'Reilly RJ, Kleppe M, McKenney AS, Shih AH, Shank K, Ahn J, Papalexi E, Spitzer B, Socci N, Viale A, Mandon E, Ebel N, Andraos R, Rubert J, Dammassa E, Romanet V, Dölemeyer A, Zender M, Heinlein M, Rampal R, Weinberg RS, Hoffman R, Sellers WR, Hofmann F, Murakami M, Baffert F, Gaul C, Radimerski T, Levine RL. Meyer SC, et al. Cancer Cell. 2015 Jul 13;28(1):15-28. doi: 10.1016/j.ccell.2015.06.006. Cancer Cell. 2015. PMID: 26175413 Free PMC article.
Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.
Shimizu T, Kubovcakova L, Nienhold R, Zmajkovic J, Meyer SC, Hao-Shen H, Geier F, Dirnhofer S, Guglielmelli P, Vannucchi AM, Feenstra JD, Kralovics R, Orkin SH, Skoda RC. Shimizu T, et al. Among authors: meyer sc. J Exp Med. 2016 Jul 25;213(8):1479-96. doi: 10.1084/jem.20151136. Epub 2016 Jul 11. J Exp Med. 2016. PMID: 27401344 Free PMC article.
97 results